Hemophilia
We recommend
Results of Prophylactic Treatment of Severe von Willebrand Disease with Recombinant vWF
Níže citovaná studie fáze III hodnotila účinnost a bezpečnost 12měsíční profylaxe rekombinantním von Willebrandovým faktorem (rvWF) u 23 pacientů s těžkou von Willebrandovou chorobou (vWD), kteří byli dříve léčeni jen podle potřeby (při výskytu spontánního krvácení) nebo předtím užívali profylaxi vWF získaným z plazmy (pdvWF).
Smaller Volume and Faster Infusion Rate of aPCC: What Do Current Data Say About This Modification?
Podání infuze s koncentrátem aktivovaného protrombinového komplexu (aPCC) při standardizované…
Evaluation of Joint Condition in Daily Practice in the Era of New Hemophilia Treatment
With the development of new treatment options for hemophilia, there has also been progress in…
Articles on this topic
Rurioctocog alfa pegol in previously treated patients with severe hemophilia A: What findings did the long-term continuation study bring?
Rurioctocog alfa pegol (Adynovi) is a recombinant coagulation factor VIII modified by…
Position of aPCC in the Treatment of Hemophilia A Complicated by the Development of Inhibitors
Activated prothrombin complex concentrates (aPCC) are essential drugs that not only allow the…
Observational Study of Pegylated rVIII Administration in Real Clinical Practice
A recently published article by American hematologists provided valuable information about the…
Cost-effectiveness in Bleeding Control for Acquired Hemophilia A
A pharmacoeconomic analysis showed favorable cost-effectiveness of activated prothrombin…
Minimum and Optimal Factor Levels in Physically Active Hemophiliacs
Authors of a recently published study attempted to determine the value of minimum and optimal…
Immunotolerance is still the goal of management of hemophilia A with inhibitor in the era of non-factor therapy
New molecules in hemophilia therapy have raised many questions, including regarding the…
Prognostic Significance of Subclinical Joint Changes on MRI in Hemophilia
Experience shows that monitoring joint changes, especially subclinical ones, is very necessary…
Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
With new treatment options for hemophilia A without inhibitors, the question of…
Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
The aging population of individuals with hemophilia brings new experiences and challenges,…
Subscribe
E-courses on this topic
Most read on this topic
- International Recommendations for COVID-19 Vaccination in People with Bleeding Disorders
- Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
- Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures
- What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
- COVID-19: Specifics of Care for Individuals with Congenital Bleeding Disorders
- Position of aPCC in the Treatment of Hemophilia A Complicated by the Development of Inhibitors
Journal on this topic
Related topic
Interesting links